Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$4.08
-1.9%		$3.69
$2.60
▼
$14.68
$36.15M1.1143,608 shs181,825 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$4.71
-3.5%		$7.15
$4.60
▼
$70.60
$35.96M2.2123,136 shs33,991 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.00
-3.9%		$5.99
$8.50
▼
$23.00
$37.51MN/A37,647 shs8,281 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.31
-0.8%		$0.36
$0.29
▼
$2.88
$9.66M2.121.13 million shs289,858 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
-1.92%-0.24%+9.38%+17.58%-62.33%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-3.48%-16.81%-38.19%-45.35%-86.84%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-3.92%-2.28%-16.29%-28.83%-61.24%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-0.81%-2.57%-18.44%-70.99%-78.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$4.08
-1.9%		$3.69
$2.60
▼
$14.68
$36.15M1.1143,608 shs181,825 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$4.71
-3.5%		$7.15
$4.60
▼
$70.60
$35.96M2.2123,136 shs33,991 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$6.00
-3.9%		$5.99
$8.50
▼
$23.00
$37.51MN/A37,647 shs8,281 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.31
-0.8%		$0.36
$0.29
▼
$2.88
$9.66M2.121.13 million shs289,858 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
-1.92%-0.24%+9.38%+17.58%-62.33%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-3.48%-16.81%-38.19%-45.35%-86.84%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-3.92%-2.28%-16.29%-28.83%-61.24%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-0.81%-2.57%-18.44%-70.99%-78.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.40
Hold$110.002,235.46% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
2.75
Moderate Buy$10.003,152.03% Upside

Current Analyst Ratings Breakdown

Latest SNTI, IZTC, BCTX, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/10/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$14.56M2.38N/AN/A$5.67 per share0.83
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$20K478.93N/AN/A$0.18 per share1.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$53.82MN/AN/AN/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$61.44M-$1.77N/AN/AN/AN/A-1,629.80%-119.72%11/12/2026 (Estimated)

Latest SNTI, IZTC, BCTX, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.33-$0.41-$0.08-$0.41N/A$0.02 million
7/30/2026Q4 2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A-$1.80N/A-$0.0850N/A$3.68 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
5.69
N/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
0.83
0.83

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.70%

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
48.70 million8.64 millionNo Data
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,0217.37 million7.14 millionOptionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3931.15 million30.17 millionNot Optionable

Recent News About These Companies

What is HC Wainwright's Forecast for SNTI Q3 Earnings?
September 27 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053760
Senti Biosciences Holdings Inc
August 11, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/SNTI
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...
July 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-for-its-gene-circuit-enabled-pipeline-including-senti-202-and-to-sharpen-its-focus-on-next-generation-1036327395
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327605/0/en/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-for-its-gene-circuit-enabled-pipeline-including-senti-202-and-to-sharpen-its-focus-on-next-generati.html
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure
May 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=marketbeat.com&utm_medium=referral
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...
May 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia
May 14, 2026  |  quiverquant.comQ
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294967/0/en/senti-biosciences-holdings-reports-first-quarter-2026-financial-results-and-highlights-advancement-of-senti-202-program-into-pivotal-phase.html
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html
Senti Biosciences Holdings Inc.
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/snti/stock-grader?gaa_ts=69986916
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
April 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026-1036015455
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272549/0/en/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026.html
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
April 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/01/3266634/0/en/senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-logic-gated-car-design-for-cell-therapies.html
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263731/0/en/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update.html
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
March 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/23/3260430/0/en/senti-biosciences-to-present-clinical-and-translational-data-on-senti-202-at-the-11th-annual-innate-killer-conference.html
Senti Biosciences Amends Lease, Restructures GeneFab Sublease
March 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/senti-biosciences-amends-lease-restructures-genefab-sublease?utm_source=marketbeat.com&utm_medium=referral
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
March 3, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/03/03/10341300.htm
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
March 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/03/3248488/0/en/senti-biosciences-to-present-at-leerink-partners-2026-global-healthcare-conference.html
Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference
February 24, 2026  |  quiverquant.comQ
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/24/3243708/0/en/senti-biosciences-to-present-at-td-cowen-46th-annual-health-care-conference.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$4.08 -0.08 (-1.92%)
Closing price 09/29/2026 04:00 PM Eastern
Extended Trading
$4.10 +0.02 (+0.44%)
As of 09/29/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$4.71 -0.17 (-3.48%)
Closing price 09/29/2026 04:00 PM Eastern
Extended Trading
$4.74 +0.04 (+0.74%)
As of 09/29/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$6.00 -0.25 (-3.92%)
As of 09/28/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Senti Biosciences stock logo

Senti Biosciences NASDAQ:SNTI

$0.31 0.00 (-0.81%)
Closing price 09/29/2026 04:00 PM Eastern
Extended Trading
$0.30 0.00 (-0.81%)
As of 09/29/2026 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas